Eli Lilly

Company Management Anat Ashkenazi – EVP & CFO Anne White – EVP & President, Lilly Neuroscience Lilly Research Laboratories Daniel Skovronsky – EVP, Chief Scientific & Medical Officer and President David Ricks – Chairman, CEO & President Ilya Yuffa – EVP of Eli Lilly and Company and President of Lilly International Joe Fletcher – SVP, IR Michael Mason – EVP & President of Lilly Diabetes Analysts Carter Gould – Barclays Bank Chris Shibutani – Goldman Sachs Group Christopher Schott – JPMorgan Chase & Co. David Risinger – Leerink Partners Evan Seigerman – BMO Capital Markets Geoff Meacham – Bank of America Merrill Lynch Laura Hindley – Berenberg Louise Chen – Cantor Fitzgerald & Co. Mohit Bansal – Wells Fargo Securities Seamus Fernandez – Guggenheim Stephen Scala – TD Cowen Terence Flynn – Morgan Stanley Timothy Anderson – Wolfe Research Trung Huynh – UBS Umer Raffat – Evercore ISI Timothy Anderson […]

Eli Lilly Q3 Adj. EPS 10 Cents Vs. $1.98 a Year Ago, Beats FactSet Consensus for Per-share Loss 18 Cents.

Eli Lilly and Company (LLY) reported Q3 non-GAAP earnings Thursday of $0.10 per diluted share, down from $1.98 a year earlier. Analysts polled by Capital IQ expected $0.67. Revenue for the quarter ended Sept. 30 was $9.50 billion, up from $6.94 billion a year earlier. Analysts surveyed by Capital IQ expected $8.99 billion. The company lowered 2023 guidance for non-GAAP earnings to $6.50 and $6.70 per share, from $9.70 to $9.90 previously. Analysts surveyed by Capital IQ expect $7.97. The drug maker also continues to expect revenue of $33.4 billion and $33.9 billion. Analysts surveyed by Capital IQ expect $33.42 billion.

Citigroup analyst Andrew Baum maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $525 to $675.

UBS analyst Trung Huynh assumes Eli Lilly (NYSE:LLY) with a Buy rating and raises Price Target to $710.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $20 to $634, 52.7x our 2024 EPS, a premium to LLY’s historical forward P/E average, justified by the company’s strong revenue and earnings growth potential. We keep our 2023 EPS estimate at $9.87 and our 2024 EPS at $12.02. Following the strong rally in LLY shares since the beginning of September (+8%), we are seeing some profit-taking activity in recent days, in our view. However, we continue to have a positive opinion on LLY. We think the company has solid long-term prospects, driven by internal innovation, but also by its recent acquisitions (Versanis Bio, Sigilon, and Dice Therapeutics), which we believe will strategically expand its portfolio.

Eli Lilly (NYSE:LLY) Q2 Revenue Rises 28% to $8.31 Bln, Well Above the FactSet Consensus of $7.58 Bln。